{"pub_date": "2016-09-20T04:00:00+0000", "subsection_name": null, "lead_paragraph": "The decision went against the recommendation of independent experts, and the agency is requiring an additional trial to confirm effectiveness.", "print_page": "1", "document_type": "article", "byline": {"person": [{"rank": 1, "organization": "", "lastname": "TAVERNISE", "firstname": "Sabrina", "role": "reported"}], "original": "By SABRINA TAVERNISE"}, "multimedia": [{"width": 190, "height": 126, "url": "images/2016/09/20/business/20DRUG/20DRUG-thumbWide.jpg", "subtype": "wide", "legacy": {"wide": "images/2016/09/20/business/20DRUG/20DRUG-thumbWide.jpg", "widewidth": "190", "wideheight": "126"}, "type": "image"}, {"width": 600, "height": 400, "url": "images/2016/09/20/business/20DRUG/20DRUG-articleLarge.jpg", "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/09/20/business/20DRUG/20DRUG-articleLarge.jpg"}, "type": "image"}, {"width": 75, "height": 75, "url": "images/2016/09/20/business/20DRUG/20DRUG-thumbStandard.jpg", "subtype": "thumbnail", "legacy": {"thumbnail": "images/2016/09/20/business/20DRUG/20DRUG-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image"}], "section_name": "Business Day", "headline": {"print_headline": "F.D.A. Clears Debated Drug That Patients Lobbied For", "main": "F.D.A. Approves Muscular Dystrophy Drug That Patients Lobbied For"}, "source": "The New York Times", "blog": [], "word_count": "747", "web_url": "http://www.nytimes.com/2016/09/20/business/fda-approves-muscular-dystrophy-drug-that-patients-lobbied-for.html", "slideshow_credits": null, "news_desk": "Business", "type_of_material": "News", "snippet": "The decision went against the recommendation of independent experts, and the agency is requiring an additional trial to confirm effectiveness....", "_id": "57e05a7b95d0e021d7987280", "abstract": "Food and Drug Administration approves eteplirsen, medication for Duchenne muscular dystrophy, overriding objections by their own experts and bowing to intense patient lobbying; vote leads stock of drug maker Sarepta Therapeutics to soar. ", "keywords": [{"rank": "1", "name": "subject", "value": "Muscular Dystrophy", "is_major": "Y"}, {"rank": "2", "name": "organizations", "value": "Food and Drug Administration", "is_major": "Y"}, {"rank": "3", "name": "organizations", "value": "Sarepta Therapeutics Inc.", "is_major": "Y"}, {"rank": "4", "name": "subject", "value": "Clinical Trials", "is_major": "N"}, {"rank": "5", "name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y"}]}